Loss of G2/M arrest correlates with radiosensitization in two human sarcoma cell lines with mutant p53

Int J Cancer. 2001 Apr 20;96(2):110-7. doi: 10.1002/ijc.1002.

Abstract

We have examined the modulation of radiosensitivity by using caffeine in two human sarcoma cell lines both with a p53 mutation (US8-93 and LMS6-93). In both cell lines a strong irradiation-induced G2/M arrest was coupled with a low rate of apoptosis. Incubation with caffeine resulted in a low percentage of S and G2/M cells, associated with an accumulation in G1. With a higher caffeine concentration, we detected a lower clonogenic survival with IC(50) at 2 mM. In both cell lines incubation with caffeine completely prevents the irradiation-induced G2/M arrest. This was connected to radiosensitization, but without direct correlation to an induction of apoptosis. The effect of radiosensitization rose with higher irradiation doses. However, in comparison with LMS6-93, it was stronger in cell line US8-93. A higher radiosensitization in US8-93 correlated with the prevention of strong irradiation-induced G2/M response and higher initial DNA damage. Results of Western hybridization reveal a p53-independent mechanism of radiosensitization caused by caffeine. Our findings suggest that modulation in G2/M regulation may affect a common checkpoint for tumor cells with defective p53 function. Furthermore, our results show that the enhancer effect of caffeine is dependent on a strong reduction in the number of G2/M arrested cells and on an inhibition of DNA damage repair after irradiation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenocarcinoma / pathology
  • Adenocarcinoma / radiotherapy*
  • Adenocarcinoma / surgery*
  • Alleles
  • Apoptosis
  • Blotting, Western
  • Caffeine / pharmacology
  • Cell Survival
  • Combined Modality Therapy
  • Comet Assay
  • DNA Damage / radiation effects
  • Disease-Free Survival
  • Dose-Response Relationship, Radiation
  • G2 Phase*
  • Genes, p53*
  • Humans
  • Inhibitory Concentration 50
  • Male
  • Mitosis*
  • Mutation*
  • Nuclear Proteins*
  • Phosphodiesterase Inhibitors / pharmacology
  • Prostate-Specific Antigen / biosynthesis
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / radiotherapy*
  • Prostatic Neoplasms / surgery*
  • Proto-Oncogene Proteins / metabolism
  • Proto-Oncogene Proteins c-mdm2
  • Radiation Tolerance*
  • Radiotherapy / methods*
  • Recurrence
  • Risk Factors
  • Salvage Therapy
  • Sarcoma / genetics*
  • Sarcoma / radiotherapy*
  • Sensitivity and Specificity
  • Time Factors
  • Tumor Cells, Cultured

Substances

  • Nuclear Proteins
  • Phosphodiesterase Inhibitors
  • Proto-Oncogene Proteins
  • Caffeine
  • MDM2 protein, human
  • Proto-Oncogene Proteins c-mdm2
  • Prostate-Specific Antigen